Aldo Del Col Research Grant
To honour the legacy and memory of Myeloma Canada's co-founder, the Aldo Del Col Research Grant funds patient-prioritized Canadian research projects that help address the knowledge gaps in the diagnosis and treatment of myeloma and/or related plasma cell disorders that were identified through the Myeloma Priority Setting Partnership (PSP).
The Myeloma PSP is a collaborative project between the Horizon Health Network, the Maritime SPOR SUPPORT UNIT (MSSU), and Myeloma Canada, and adhered to established PSP practices set by the James Lind Alliance. (Click here for the Top 10 priority questions within the published correspondence, “The future of myeloma research in Canada and beyond: results of a James Lind Alliance priority setting partnership”.)
Research proposals must:
• be for projects of a duration of one or two years;
• address one or more of the top ten priorities for multiple myeloma research in Canada as identified through the Myeloma PSP. Click here to access the Top Ten Myeloma Research Priorities;
• satisfy one or more of Myeloma Canada’s Funded Research Principles. The research in question must have a direct impact on:
- improving the quality of life and/or survival of myeloma patients;
- increasing patient access to new myeloma therapies, new treatment combinations, or improved treatment administration;
- improving myeloma healthcare delivery.
The research should impact all Canadian patients and not just one particular Canadian centre or region. Patient involvement in the development of research protocols is an asset. Research proposals will be peer-reviewed by an Independent Research Review Committee (IRRC).
Based on the number and quality of applications, grants totaling a maximum of CDN $200,000 will be awarded in 2023. The minimum funded research award is CDN $50,000. A maximum of one (1) grant from each of the following categories will be awarded:
- Lab-based academic or bench research
- Database or real world evidence research
- Quality of life research
- Clinical research
The principal applicant must be a researcher at any career stage, and be affiliated with a Canadian university, hospital, cancer centre or research institute.
Eligible applicants must complete and submit the Aldo Del Col Research Grant Application Form prior to the posted application deadline.
As part of the application process, eligible applicants must :
- successfully answer pre-screening eligibility questions;
- accept the Applicant Terms and Conditions;
- agree to provide an interim and/or a final status update according to the length of the research proposal;
- provide an impact statement (250 words max) on the significance and potential impact of the research project..
For any questions or additional information regarding Myeloma Canada’s Aldo Del Col Research Grant, please contact Gabriele Colasurdo, Myeloma Canada’s Director of Science and Research, at [email protected].